Meeting
2024 ASCO Genitourinary Cancers Symposium
Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk of biochemical recurrence (BCR) after radical prostatectomy (RP) in the ongoing phase 3 PRIMORDIUM study.
Authors
Boris A. Hadaschik
Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany
Boris A. Hadaschik , Nicolas Mottet , Piet Ost , Cosimo De Nunzio , Nina Tunariu , Renata Zaucha , Klaus Brasso , Ignacio Osman-Garcia , Deniz Tural , Martin Lukac , Hind Stitou , Geneviève Pissart , Michela Efficace , Stefano Fanti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04557059
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 119)
DOI
10.1200/JCO.2024.42.4_suppl.119
Abstract #
119
Poster Bd #
E12
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.
First Author: Jeremie Calais
Poster
2023 ASCO Genitourinary Cancers Symposium
Early biochemical outcomes following PSMA-guided approach for biochemical relapse after prostatectomy: PSICHE trial.
First Author: Giulio Francolini
Poster
2022 ASCO Genitourinary Cancers Symposium
Salvage radiotherapy (SRT) in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer.
First Author: Markus Grabbert